Acurx Pharmaceuticals (ACXP) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.10, -5.98% vs the prior close of $1.17.
- Volume 164.43K shares, 1.2x its 50-day average.
- New SEC filings: 8-K (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
ACXP slides 6.0% to $1.10, a 52-week low. Closed at $1.10, -5.98% vs the prior close of $1.17. Day range $1.07–$1.19, opened at $1.18.
ACXP daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ACXP slides 6.0% to $1.10, a 52-week low
- Closed at $1.10, -5.98% vs the prior close of $1.17. Day range $1.07–$1.19, opened at $1.18.
- Volume was 164.43K shares, 1.2x its 50-day average of 132.97K.
- Price is -20.0% vs its 50-day average ($1.37) and -46.6% vs its 200-day average ($2.06).
- 52-week range $1.07–$7.54; today's close sits at 0% of that range, 85.4% below the 52-week high.
Oct 15, 2026 — ACXP rises 1.7% to $1.17
- Closed at $1.17, +1.74% vs the prior close of $1.15. Day range $1.15–$1.22, opened at $1.20.
- Volume was 98.30K shares, 0.7x its 50-day average of 131.97K.
- Price is -15.3% vs its 50-day average ($1.38) and -43.4% vs its 200-day average ($2.07).
- 52-week range $1.15–$7.81; today's close sits at 0% of that range, 85.0% below the 52-week high.
Oct 14, 2026 — ACXP slides 4.2% to $1.15, a 52-week low
- Closed at $1.15, -4.17% vs the prior close of $1.20. Day range $1.15–$1.22, opened at $1.20.
- Volume was 80.80K shares, 0.6x its 50-day average of 132.51K.
- Price is -17.2% vs its 50-day average ($1.39) and -44.6% vs its 200-day average ($2.08).
- 52-week range $1.15–$7.87; today's close sits at 0% of that range, 85.4% below the 52-week high.
Oct 13, 2026 — ACXP slides 6.2% to $1.20, a 52-week low
- Closed at $1.20, -6.25% vs the prior close of $1.28. Day range $1.20–$1.29, opened at $1.29.
- Volume was 97.60K shares, 0.7x its 50-day average of 134.51K.
- Price is -13.9% vs its 50-day average ($1.39) and -42.5% vs its 200-day average ($2.09).
- 52-week range $1.20–$7.98; today's close sits at 0% of that range, 85.0% below the 52-week high.
Oct 12, 2026 — ACXP rises 0.8% to $1.28
- Closed at $1.28, +0.79% vs the prior close of $1.27. Day range $1.25–$1.30, opened at $1.28.
- Volume was 80.80K shares, 0.6x its 50-day average of 133.44K.
- Price is -8.5% vs its 50-day average ($1.40) and -39.0% vs its 200-day average ($2.10).
- 52-week range $1.23–$7.98; today's close sits at 1% of that range, 84.0% below the 52-week high.
Oct 9, 2026 — ACXP rises 1.6% to $1.27
- Closed at $1.27, +1.60% vs the prior close of $1.25. Day range $1.24–$1.28, opened at $1.24.
- Volume was 40.20K shares, 0.3x its 50-day average of 134.83K — lighter than usual.
- Price is -9.4% vs its 50-day average ($1.40) and -39.8% vs its 200-day average ($2.11).
- 52-week range $1.23–$8.14; today's close sits at 1% of that range, 84.4% below the 52-week high.
Oct 8, 2026 — ACXP slides 3.8% to $1.25, a 52-week low, 3 down days in a row
- Closed at $1.25, -3.85% vs the prior close of $1.30. Day range $1.24–$1.28, opened at $1.28.
- Volume was 74.30K shares, 0.5x its 50-day average of 135.12K — lighter than usual.
- Price is -11.0% vs its 50-day average ($1.40) and -41.1% vs its 200-day average ($2.12).
- 52-week range $1.23–$8.34; today's close sits at 0% of that range, 85.0% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ACXP dips 0.8% to $1.30
- Closed at $1.30, -0.76% vs the prior close of $1.31. Day range $1.28–$1.33, opened at $1.32.
- Volume was 78.00K shares, 0.6x its 50-day average of 134.58K — lighter than usual.
- Price is -7.6% vs its 50-day average ($1.41) and -39.0% vs its 200-day average ($2.13).
- 52-week range $1.23–$8.34; today's close sits at 1% of that range, 84.4% below the 52-week high.
Oct 6, 2026 — ACXP ends flat (+0.0%) to $1.31
- Closed at $1.31, +0.00% vs the prior close of $1.31. Day range $1.28–$1.33, opened at $1.30.
- Volume was 41.30K shares, 0.3x its 50-day average of 134.87K — lighter than usual.
- Price is -7.1% vs its 50-day average ($1.41) and -38.8% vs its 200-day average ($2.14).
- 52-week range $1.23–$8.34; today's close sits at 1% of that range, 84.3% below the 52-week high.
Oct 5, 2026 — ACXP jumps 3.1% to $1.31
- Closed at $1.31, +3.15% vs the prior close of $1.27. Day range $1.25–$1.36, opened at $1.25.
- Volume was 109.70K shares, 0.8x its 50-day average of 134.15K.
- Price is -7.2% vs its 50-day average ($1.41) and -39.2% vs its 200-day average ($2.15).
- 52-week range $1.23–$8.34; today's close sits at 1% of that range, 84.3% below the 52-week high.
Oct 2, 2026 — ACXP rises 0.8% to $1.27
- Closed at $1.27, +0.79% vs the prior close of $1.26. Day range $1.25–$1.28, opened at $1.28.
- Volume was 79.40K shares, 0.6x its 50-day average of 134.66K — lighter than usual.
- Price is -10.2% vs its 50-day average ($1.41) and -41.3% vs its 200-day average ($2.16).
- 52-week range $1.23–$8.34; today's close sits at 1% of that range, 84.8% below the 52-week high.
ACXP latest news & SEC filings
Every SEC filing by or about ACXP in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Sep 17, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 17, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 8, 2026 · Form S-1 — Registration statement (S-1)
Registration statement (S-1) — registering new shares, usually for an IPO or offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 1, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Sep 1, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Sep 1, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$2.25M (prior year -$2.25M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.53 (prior year -$1.89) (loss narrowed vs Jun 30, 2025)
Things to know before you trade ACXP
- Last results release: May 13, 2025 (8-K Item 2.02). Previous ones: Mar 18, 2025, Nov 13, 2024, Aug 9, 2024. Based on that rhythm, the next report is likely around Aug 12, 2025 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.23% (largest 6.2%).
- Liquidity: about 101.57K shares (≈$111.73K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.10 vs a range of $1.07–$7.54 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:20 on Aug 5, 2025
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 16, 2026; 10-Q Aug 13, 2026; 10-Q May 11, 2026.
- Share count: 5.27M shares outstanding (Aug 13, 2026), +232.5% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ACXP market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.18 | 1.19 | 1.07 | 1.10 | 164.43K |
| Oct 15, 2026 | 1.20 | 1.22 | 1.15 | 1.17 | 98.30K |
| Oct 14, 2026 | 1.20 | 1.22 | 1.15 | 1.15 | 80.80K |
| Oct 13, 2026 | 1.29 | 1.29 | 1.20 | 1.20 | 97.60K |
| Oct 12, 2026 | 1.28 | 1.30 | 1.25 | 1.28 | 80.80K |
| Oct 9, 2026 | 1.24 | 1.28 | 1.24 | 1.27 | 40.20K |
| Oct 8, 2026 | 1.28 | 1.28 | 1.24 | 1.25 | 74.30K |
| Oct 7, 2026 | 1.32 | 1.33 | 1.28 | 1.30 | 78.00K |
| Oct 6, 2026 | 1.30 | 1.33 | 1.28 | 1.31 | 41.30K |
| Oct 5, 2026 | 1.25 | 1.36 | 1.25 | 1.31 | 109.70K |
| Oct 2, 2026 | 1.28 | 1.28 | 1.25 | 1.27 | 79.40K |
| Oct 1, 2026 | 1.27 | 1.29 | 1.25 | 1.26 | 64.60K |
| Sep 30, 2026 | 1.32 | 1.32 | 1.23 | 1.26 | 130.50K |
| Sep 29, 2026 | 1.38 | 1.38 | 1.27 | 1.30 | 161.60K |
| Sep 28, 2026 | 1.36 | 1.36 | 1.33 | 1.34 | 52.80K |
| Sep 25, 2026 | 1.38 | 1.38 | 1.35 | 1.36 | 134.00K |
| Sep 24, 2026 | 1.39 | 1.39 | 1.35 | 1.36 | 48.10K |
| Sep 23, 2026 | 1.36 | 1.38 | 1.35 | 1.37 | 58.60K |
| Sep 22, 2026 | 1.34 | 1.39 | 1.30 | 1.36 | 156.20K |
| Sep 21, 2026 | 1.39 | 1.41 | 1.31 | 1.33 | 280.20K |
About Acurx Pharmaceuticals
Acurx Pharmaceuticals (ACXP) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in STATEN ISLAND, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1736243.
ACXP board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jack H Dean | Director | Apr 22, 2026 |
| Robert J Deluccia | Director | Apr 22, 2026 |
| James J. Donohue | Director | Apr 22, 2026 |
| Thomas L Harrison | Director | Apr 22, 2026 |
| David P Luci | President and CEO | Apr 22, 2026 |
| Carl Sailer | Director | Apr 22, 2026 |
| Joseph C Scodari | Director | Apr 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| David P Luci | President and CEO | Apr 22, 2026 |
| Robert G. Shawah | Chief Financial Officer | Apr 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
ACXP financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-7.97M | -5.32 | $-6.79M |
| Dec 31, 2024 | — | $-14.10M | -17.45 | $-10.38M |
| Dec 31, 2023 | — | $-14.58M | -1.15 | $-9.80M |
| Dec 31, 2022 | — | $-12.09M | -1.12 | $-7.54M |
| Dec 31, 2021 | — | $-12.75M | -1.49 | $-5.01M |
Latest balance sheet: total assets $10.98M, total liabilities $2.83M, cash $14.46M (as of Jun 30, 2026).
ACXP earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| May 13, 2025 | 8-K Item 2.02 (results) | $7.60 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $8.12 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $36.40 |
| Aug 9, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| Mar 18, 2024 | 8-K Item 2.02 (results) | — |
| Nov 14, 2023 | 8-K Item 2.02 (results) | — |
| Aug 14, 2023 | 8-K Item 2.02 (results) | — |
| Mar 16, 2023 | 8-K Item 2.02 (results) | — |
| Nov 14, 2022 | 8-K Item 2.02 (results) | — |
| Aug 15, 2022 | 8-K Item 2.02 (results) | — |
| Jul 25, 2022 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ACXP
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.